{"doi":"10.1016/s1359-6349(04)80526-3","title":"518 Alterations of topoisomerase IIalpha, associated with in vivo resistance to tafluposide, are partially reversible","abstract":null,"journal":"European Journal of Cancer Supplements","year":2004,"id":37097,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":186633,"name":"L. Creancier","orcid":null,"position":1,"is_corresponding":false},{"id":186634,"name":"Y. Menon","orcid":null,"position":2,"is_corresponding":false},{"id":186635,"name":"N. Chansard","orcid":null,"position":3,"is_corresponding":false},{"id":186636,"name":"J. Astruc","orcid":null,"position":4,"is_corresponding":false},{"id":141746,"name":"S. Roy","orcid":null,"position":5,"is_corresponding":false},{"id":186637,"name":"J.-M. Barret","orcid":null,"position":6,"is_corresponding":false},{"id":186638,"name":"C. Bailly","orcid":null,"position":7,"is_corresponding":false},{"id":186632,"name":"A. Kruczynski","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"18998881","pmcid":null,"openalex_id":"https://openalex.org/W2057650488","authors":[],"funders":[],"total_grants":0,"fwci":0.0,"citation_percentile":0.0967747,"influential_citations":0,"citation_trend":[],"oa_status":"closed","license":"https://www.elsevier.com/legal/tdmrep-license","oa_locations":[{"url":"https://api.elsevier.com/content/article/PII:S1359634904805263?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S1359634904805263?httpAccept=text/plain","host_type":"publisher"},{"url":"https://doi.org/10.1016/s1359-6349(04)80526-3","host_type":"journal"}],"fields_of_study":["Cancer therapeutics and mechanisms","Cancer Treatment and Pharmacology","DNA Repair Mechanisms","Medicine","Biology"],"mesh_terms":[],"keywords":["Ku70","Ku80","DNA ligase","Non-homologous end joining","DNA repair protein XRCC4","Genome instability","DNA repair","Biology","Homologous recombination","DNA damage","DNA-PKcs","Molecular biology","Cell biology","DNA","Genetics","Gene","DNA-binding protein","DNA mismatch repair","Transcription factor"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-06-10T18:25:26.283387Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}